367 related articles for article (PubMed ID: 27216065)
1. Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model.
Hu Y; Pertinez H; Ortega-Muro F; Alameda-Martin L; Liu Y; Schipani A; Davies G; Coates A
Antimicrob Agents Chemother; 2016 Aug; 60(8):4778-85. PubMed ID: 27216065
[TBL] [Abstract][Full Text] [Related]
2. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice.
Grosset J; Truffot-Pernot C; Lacroix C; Ji B
Antimicrob Agents Chemother; 1992 Mar; 36(3):548-51. PubMed ID: 1622164
[TBL] [Abstract][Full Text] [Related]
3. Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.
Lanoix JP; Betoudji F; Nuermberger E
Antimicrob Agents Chemother; 2016 Feb; 60(2):1091-6. PubMed ID: 26643352
[TBL] [Abstract][Full Text] [Related]
4. Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse Model.
Liu Y; Pertinez H; Davies GR; Gillespie SH; Coates AR; Hu Y
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661869
[TBL] [Abstract][Full Text] [Related]
5. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
Almeida D; Nuermberger E; Tasneen R; Rosenthal I; Tyagi S; Williams K; Peloquin C; Grosset J
Antimicrob Agents Chemother; 2009 Oct; 53(10):4178-84. PubMed ID: 19620331
[TBL] [Abstract][Full Text] [Related]
6. Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
Park JS; Lee JY; Lee YJ; Kim SJ; Cho YJ; Yoon HI; Lee CT; Song J; Lee JH
Antimicrob Agents Chemother; 2016 Jan; 60(1):92-8. PubMed ID: 26459901
[TBL] [Abstract][Full Text] [Related]
7. [Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)].
Grosset J; Truffot C; Fermanian J; Lecoeur H
Pathol Biol (Paris); 1982 Jun; 30(6):444-8. PubMed ID: 6810288
[TBL] [Abstract][Full Text] [Related]
8. Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model.
Byrne ST; Denkin SM; Gu P; Nuermberger E; Zhang Y
J Med Microbiol; 2007 Aug; 56(Pt 8):1047-1051. PubMed ID: 17644711
[TBL] [Abstract][Full Text] [Related]
9. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
[TBL] [Abstract][Full Text] [Related]
10. [Phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis isolated in Poland].
Napiórkowska A; Augustynowicz-Kopeć E; Zwolska Z
Pneumonol Alergol Pol; 2010; 78(4):256-62. PubMed ID: 20665445
[TBL] [Abstract][Full Text] [Related]
11. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
12. The effect of growth rate on pyrazinamide activity in Mycobacterium tuberculosis - insights for early bactericidal activity?
Pullan ST; Allnutt JC; Devine R; Hatch KA; Jeeves RE; Hendon-Dunn CL; Marsh PD; Bacon J
BMC Infect Dis; 2016 May; 16():205. PubMed ID: 27184366
[TBL] [Abstract][Full Text] [Related]
13. Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria.
Liu Y; Pertinez H; Ortega-Muro F; Alameda-Martin L; Harrison T; Davies G; Coates A; Hu Y
J Antimicrob Chemother; 2018 Mar; 73(3):724-731. PubMed ID: 29244108
[TBL] [Abstract][Full Text] [Related]
14. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.
Ibrahim M; Truffot-Pernot C; Andries K; Jarlier V; Veziris N
Am J Respir Crit Care Med; 2009 Sep; 180(6):553-7. PubMed ID: 19590024
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of katG Ser315 substitution and rpoB mutations in isoniazid-resistant Mycobacterium tuberculosis isolates from Brazil.
Höfling CC; Pavan EM; Giampaglia CM; Ferrazoli L; Aily DC; de Albuquerque DM; Ramos MC
Int J Tuberc Lung Dis; 2005 Jan; 9(1):87-93. PubMed ID: 15675556
[TBL] [Abstract][Full Text] [Related]
16. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide.
Lecoeur HF; Truffot-Pernot C; Grosset JH
Am Rev Respir Dis; 1989 Nov; 140(5):1189-93. PubMed ID: 2817579
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of pulmonary tuberculosis in patients with discordant phenotypic isoniazid resistance testing.
Kim S; Lee H; Park HY; Jeon K; Huh HJ; Lee NY; Jeong BH
Respir Med; 2017 Dec; 133():6-11. PubMed ID: 29173450
[TBL] [Abstract][Full Text] [Related]
18. Treatment of isoniazid-resistant pulmonary tuberculosis.
Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Lim SY; Lim SY; Koh WJ
BMC Infect Dis; 2008 Jan; 8():6. PubMed ID: 18211720
[TBL] [Abstract][Full Text] [Related]
19. Lower cytotoxicity, high stability, and long-term antibacterial activity of a poly(methacrylic acid)/isoniazid/rifampin nanogel against multidrug-resistant intestinal Mycobacterium tuberculosis.
Chen T; Li Q; Guo L; Yu L; Li Z; Guo H; Li H; Zhao M; Chen L; Chen X; Zhong Q; Zhou L; Wu T
Mater Sci Eng C Mater Biol Appl; 2016 Jan; 58():659-65. PubMed ID: 26478357
[TBL] [Abstract][Full Text] [Related]
20. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
